[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cataract\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cataract":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,112,0,25,[9,43,73,92,118,138,155,174,214,242,263,284,308,329,358,385,413,435,461,495,515,543,565,588,614],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644657","small-rna-trf-31-changes-in-patients-with-age-related-cataract-100644657",false,"NCT07672899","Small RNA tRF-31 Changes in Patients With Age-Related Cataract","Biphasic Dynamics of the tRNA-derived Small RNA tRF-31 Set the Lens Oxidative Survival Threshold by Restraining HIPK2-mediated Dual-track Lethality in Age-related Cataract","Inclusion Criteria:\n\nPatients older than 18 years. Clinically diagnosed with age-related cataract (ARC) and have clear surgical indications for routine phacoemulsification combined with intraocular lens (IOL) implantation. Scheduled to undergo cataract extraction and intraocular lens implantation. Completed routine preoperative corneal endothelial specular microscopy, providing objective data including cell density, coefficient of variation of cell area, and the proportion of hexagonal cells. Provided signed written informed consent.\n\nExclusion Criteria:\n\nHistory of ocular trauma, glaucoma, episodes of active uveitis, or previous intraocular surgery. Presence of severe systemic diseases rendering the patient unsuitable for surgery. Poor patient compliance or coexisting psychiatric disorders. Severe systemic metabolic syndromes (e.g., diabetes). Diagnosis of high myopia. Current participation in other clinical trials or likelihood of being lost to follow-up.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the expression characteristics and clinical relevance of the tRF-31\u002FHIPK2 signaling axis in adults over 18 years old with age-related cataract (ARC). The main questions it aims to answer are: Is there a correlation between the relative expression levels of tRF-31 and its target gene HIPK2 in the anterior lens capsule and the clinical severity (Emery-Little grading system) of age-related cataracts? Does oxidative stress in the anterior segment microenvironment have a potential bystander effect on the state of the corneal endothelium? Participants will:Undergo routine preoperative ophthalmologic examinations, including visual acuity tests, slit-lamp photography, and corneal endothelial cell counting. Undergo standard cataract surgery (phacoemulsification combined with intraocular lens implantation) as part of their regular medical care. Allow researchers to collect and analyze their anterior lens capsule tissue, which is routinely removed and typically discarded as medical waste during the standard continuous curvilinear capsulorhexis (CCC) step of the surgery.",[25],"Cataract",[27,28,29],"age-related cataract","oxidative stress","tRNA-derived small RNA","RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-29","ACTUAL",{"date":36,"type":34},"2026-06-17",{"date":38,"type":21},"2026-09-16",{"name":40,"class":41},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100643626","effects-of-oxygen-cage-support-during-cataract-surgery-100643626","NCT07632326","Effects of Oxygen Cage Support During Cataract Surgery","The Effect of Oxygen Support Cage Material Use During Cataract Surgery on Operation Time, Anxiety, Physiological Parameters, and Patient Experiences: A Mixed Methods Study","Inclusion Criteria\n\n* Willing to participate in the study voluntarily and provides informed consent\n* Aged 18 years or older\n* Having no hearing or cognitive impairments\n* Undergoing cataract surgery for the first time Exclusion Criteria\n* Conversion from local anesthesia to general anesthesia during the surgery\n* Patient's non-participation or refusal to complete the anxiety assessment during the surgery","90 Years",{"count":52,"type":21},70,"INTERVENTIONAL",[55],"NA","Cataract is an ocular disorder resulting from lens opacity; it stands as the most common cause of preventable blindness worldwide and significantly impairs the quality of life in elderly individuals. Surgical treatment utilizing small-incision phacoemulsification is the most effective solution for cataracts. Cataract surgery is generally performed under local anesthesia, which requires patients to remain awake throughout the operation, thereby potentially increasing their anxiety experiences. Elevated anxiety not only reduces patient comfort but can also lead to alterations in physiological parameters and a prolongation of the operation time. Furthermore, it is observed that the surgical drapes used to maintain the sterility of the surgical field during the operation cause discomfort to the patient. The weight and positioning of these drapes can cover the patient's mouth and nose area during the ongoing surgery, creating a sensation of difficulty in breathing (dyspnea). In addition to these circumstances, standard oxygen support is provided to the patient during cataract surgery performed under local anesthesia. This support is administered nasally via an open-ended oxygen tubing from beneath the surgical drape, aiming to ease the patient's respiration. However, when the oxygen flow rate is increased based on the patient's needs, high-velocity and high-concentration oxygen administration is observed to cause mucosal dryness, which shortly triggers reflex-induced irritative coughing attacks. For these reasons, it is crucial to keep anxiety under control, provide oxygen to prevent hypoxia, and monitor physiological parameters during cataract surgery.",[25],[59,60,61,62,63],"Cataract Surgery","Oxygen Support","Anxiety","Patient Experience","Surgical Nursing","NOT_YET_RECRUITING",{"date":66,"type":34},"2026-06-26",{"date":68,"type":21},"2026-07-01",{"date":70,"type":21},"2027-05-01",{"name":72,"class":41},"Ataturk University",{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":42},"100641197","clareon-truplus-vs-tecnis-eyhance-iols-in-cataract-patients-100641197","NCT07658040","Clareon TruPlus vs Tecnis Eyhance IOLs in Cataract Patients","Visual and Patient Reported Outcomes Comparing Clareon TruPlus IOL and Tecnis Eyhance IOLs in Normal Cataract Patients: Stage 1","Inclusion Criteria:\n\n* Willing and able to understand and sign informed consent.\n* Adult patient diagnosed with age-related cataracts bilaterally.\n* Planned bilateral cataract removal and with bilateral implantation of the Clareon TruPlus IOL\u002FToric BLF (T3-T5) or Tecnis Eyhance IOL\u002FEyhance Toric (equivalent to T3-T5).\n* Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20\u002F25) or better in both eyes postoperatively as determined by surgeon.\n* Residual astigmatism expected to be \\\u003C= 0.50 diopters in both eyes postoperatively as determined by surgeon (After using either toric IOL or arcuate incision with laser or manual LRI).\n* Normal ocular findings aside from cataract.\n\nExclusion Criteria:\n\n* Moderate-severe corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation.\n* Previous history of any ocular surgery including corneal refractive surgery.\n* History of amblyopia or monofixation syndrome with poor stereoscopic vision.\n* Participants desiring monovision.\n* Any planned simultaneous\u002Fcombined procedures at time of cataract surgery (e.g. MIGs).\n* Participation in another clinical study that could interfere with the results.\n* Any active ocular infection or inflammation.",{"count":52,"type":21},"This study is a prospective, randomized, two-arm, single-center, single-surgeon, double-masked (subject and assessor) comparative study. It involves bilateral implantation of intraocular lenses (IOLs), comparing Clareon TruPlus IOL and Tecnis Eyhance IOLs in normal cataract patients. The study will be conducted at one site and will include a pre-operative visit and a 3-month post-operative assessment.",[25],"2026-06-16",{"date":85,"type":34},"2026-06-18",{"date":87,"type":21},"2026-08-09",{"date":89,"type":21},"2027-08-09",{"name":91,"class":41},"Gainesville Eye Associates",{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":53,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100641136","effect-of-dry-eye-treatment-on-corneal-astigmatism-measurements-100641136","NCT07657858","Effect of Dry Eye Treatment on Corneal Astigmatism Measurements","Effect of Dry Eye and Ocular Surface Treatment on Agreement and Repeatability of Corneal Astigmatism Measurements Among Three Devices","Inclusion Criteria:\n\n* Patients with age-related cataract undergoing preoperative ocular examination.\n* Ability to complete ocular surface evaluation, including the Ocular Surface\n* Disease Index questionnaire, non-invasive tear film break-up time, tear meniscus height, Schirmer test, and ocular surface staining.\n* Ability to complete repeated corneal astigmatism measurements using IOLMaster 700, Pentacam AXL, and iTrace Prime.\n* Ability to maintain stable fixation during device measurements. Provision of written informed consent.\n\nExclusion Criteria:\n\n* Previous ocular surgery or ocular trauma.\n* Corneal degeneration, corneal dystrophy, or other corneal diseases that could affect corneal measurements.\n* Active corneal or conjunctival infection.\n* Uveitis.\n* Use of any topical eye drops within 24 hours before examination.\n* Use of antiglaucoma medications.\n* Contact lens wear within 1 month before examination.\n* Previous or ongoing treatment for dry eye disease.\n* Poor fixation during device measurements.\n* Poor-quality measurements from any study device",{"count":100,"type":21},400,[55],"This prospective single-center study evaluates the effect of dry eye disease and short-term ocular surface treatment on the agreement and repeatability of corneal astigmatism measurements in patients with age-related cataract. Participants undergoing preoperative cataract evaluation are classified into a control group or a dry eye disease group according to ocular surface symptoms and objective tear film findings.\n\nAll participants undergo ocular surface assessment and repeated corneal measurements using three commonly used devices: IOLMaster 700, Pentacam AXL, and iTrace Prime. Measurements include keratometric corneal astigmatism, total corneal astigmatism, and vector components of astigmatism. Patients with dry eye disease receive 0.3% sodium hyaluronate eye drops four times daily for 2 weeks, after which ocular surface assessment and device measurements are repeated.\n\nThe primary objective is to determine whether dry eye disease reduces interdevice agreement and test-retest repeatability of corneal astigmatism measurements, and whether short-term ocular surface treatment improves measurement stability. Interdevice agreement is assessed using Bland-Altman analysis, and repeatability is evaluated using within-subject standard deviation, test-retest repeatability, and intraclass correlation coefficient.",[104,25],"Dry Eye",[106,25,107,108,109],"Dry Eye Disease","Corneal Astigmatism","Ocular Surface",";Biometry","2026-06-15",{"date":85,"type":34},{"date":113,"type":34},"2026-01-01",{"date":115,"type":21},"2030-12-31",{"name":117,"class":41},"Jin Yang",{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":42},"100642690","lacrifill-for-ocular-surface-optimization-in-cataract-surgery-100642690","NCT07648095","Lacrifill for Ocular Surface Optimization in Cataract Surgery","Evaluation of Lacrifill™ Canalicular Filler for Optimization of Ocular Surface Parameters and Biometric Precision in Prospective Cataract Surgery Patients With Dry Eye Disease","Inclusion Criteria:\n\n* Age \\>= 40 years\n* Diagnosed dry eye (OSDI \\>= 13, TBUT \\\u003C 10 sec, or Oxford staining \\>= Grade 2)\n* No recent ocular surgeries (\\\u003C6 months)\n* No significant changes in DED regimen within last 1 month\n\nExclusion Criteria:\n\n* Previous punctal plugs or canalicular cautery\n* Active ocular inflammation or corneal pathology unrelated to DED","40 Years",{"count":127,"type":21},65,"This is a single-site observational study designed to evaluate the efficacy of Lacrifill™ canalicular filler in optimizing ocular surface parameters and biometric precision in prospective cataract surgery patients with dry eye disease (DED).",[25],"2026-06-12",{"date":110,"type":34},{"date":133,"type":21},"2026-07-15",{"date":135,"type":21},"2027-07-15",{"name":137,"class":41},"The Eye Institute of West Florida",{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":151,"leadSponsor":153,"locationsCount":42},"100643416","post-refractive-iol-outcomes-with-clareon-truplus-100643416","NCT07610226","Post-refractive IOL Outcomes With Clareon TruPlus","Inclusion Criteria:\n\n* Willing and able to understand and sign informed consent.\n* Adult patients (\\>45 years old) undergoing age-related cataract surgery that previously had myopic corneal refractive surgery.\n* Dominant eye targeted for emmetropia, non-dominant eye may be targeted for ≤-0.75D (mini-monovision).\n* Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20\u002F25) or better in both eyes pre-operatively as determined by surgeon.\n* Normal ocular findings aside from cataract.\n\nExclusion Criteria:\n\n* Moderate-severe corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases, diabetic retinopathy that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation.\n* Previous history of any ocular surgery, except for myopic LASIK or PRK.\n* Previous hyperopic refractive surgery.\n* Corneal HOA ≥1.0 µm (RMS) with OPD at 4mm scan.\n* Any active ocular infection or inflammation.",{"count":145,"type":21},35,"This is a prospective, single-arm, single-center, single-surgeon study evaluating the Clareon TruPlus IOL in post-refractive cataract patients. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the PRISQ Questionnaire.",[25],"2026-06-10",{"date":130,"type":34},{"date":31,"type":21},{"date":152,"type":21},"2027-06-23",{"name":154,"class":41},"Laser Defined Vision",{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":42},"100642852","visual-and-patient-reported-outcomes-with-clareon-truplus-100642852","NCT07648355","Visual and Patient Reported Outcomes With Clareon TruPlus","Visual and Patient Reported Outcomes of Clareon TruPlus IOL in Cataract Surgery Patients","Inclusion Criteria:\n\n* Willing and able to understand and sign informed consent.\n* Adult patients (\\>40 years old) undergoing age-related cataract surgery with expected best-corrected visual outcomes of 20\u002F25 or better in both eyes pre-operatively as determined by surgeon and with regular corneal astigmatism correctable to less than 0.75 diopters post-operatively with no more than a T6 toric power IOL.\n* Normal ocular findings aside from cataract and mild dry eye.\n\nExclusion Criteria:\n\n* Subjects targeted for monovision.\n* Moderate-severe corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases, diabetic retinopathy that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, amblyopia, zonular laxity or dehiscence, pseudoexfoliation.\n* Previous history of any ocular surgery including LASIK (excluding minor lid procedures).\n* Patients with irregular astigmatism\u002Ftopography, corneal dystrophies, and pupil abnormalities.\n* Participation in another clinical study that could interfere with the results.\n* Any active ocular infection or inflammation.",{"count":163,"type":21},40,"This is a prospective, single-site, two-surgeon, single-arm, observational study evaluating the Clareon TruPlus IOL. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the IOLSAT Questionnaire.",[25],"2026-06-09",{"date":110,"type":34},{"date":169,"type":34},"2026-06-02",{"date":171,"type":21},"2027-07-11",{"name":173,"class":41},"OVO LASIK + Lens",{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":181,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":184,"conditions":185,"keywords":201,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":42},"100643686","development-of-a-mobile-terminal-based-intelligent-detection-system-for-multiple-anterior-segment-diseases-of-the-eye-100643686","NCT07634913","Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye","LENS","Inclusion Criteria:\n\n* Adults aged 18 years or older;\n* Willing to participate and able to provide written informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* Unable to cooperate with anterior segment image capture (including smartphone-based photography or slit-lamp biomicroscopy).",true,{"count":183,"type":21},3000,"This is a multi-center, cross-sectional study evaluating a smartphone-based artificial intelligence (AI) system for anterior segment eye disease screening. The system is designed to identify 16 clinically important anterior segment conditions from images captured using a standard Android smartphone. A core design feature of the system is that all image analysis is performed entirely on the smartphone itself, without requiring internet connectivity or cloud-based server infrastructure.\n\nThe study is motivated by a structural challenge in the deployment of medical AI: systems that depend on cloud infrastructure for inference are non-functional in settings without reliable internet access, which disproportionately excludes populations in low-resource regions where the burden of preventable eye disease is highest. This study evaluates whether an on-device AI system, designed with operational constraints as a primary engineering objective, can deliver clinically acceptable diagnostic performance while remaining operable under real-world connectivity limitations.\n\nThe study comprises five evaluation components. First, the diagnostic performance of the AI system is benchmarked against board-certified ophthalmologists of varying seniority on a standardized set of smartphone-captured anterior segment images. Second, the usability of the system is evaluated among non-medical users who perform self-administered screening with minimal instruction, with per-screening time recorded across consecutive attempts to characterize the learning curve. Third, a head-to-head field trial directly compares the on-device AI system against a functionally equivalent cloud-based deployment of the same model architecture across key operational dimensions including screening duration, diagnostic performance, and user acceptability. Fourth, population-level screening is conducted among consecutively enrolled community residents at two low-resource sites, with per-disease sensitivity and specificity calculated against reference-standard slit-lamp examinations. Fifth, pre-specified health-economic and environmental analyses compare the two deployment modalities in terms of per-person screening cost, cost-effectiveness, per-inference electricity consumption, and projected carbon emissions at scale.\n\nThe reference standard for all diagnostic comparisons is slit-lamp biomicroscopic examination performed by board-certified ophthalmologists. The study is designed and reported in accordance with the DECIDE-AI reporting guideline for early-stage clinical evaluation of AI-driven decision-support systems.",[186,25,187,188,189,190,191,192,193,194,195,196,197,198,199,200],"Artifical Intelligence","Pterygium","Keratopathy","Subconjunctival Hemorrhage","Conjunctivitis","Stye","Blepharitis","Entropion","Ectropion","Exophthalmos","Irregular Pupils","Conjunctival Concretions","Hyphema","Hypopyon","Corneal Transplant Status",[202,203,204,205],"Artificial Intelligence","Standalone Deployment","Smartphone","Eye Disease Screening","2026-06-08",{"date":166,"type":34},{"date":209,"type":34},"2023-12-12",{"date":211,"type":21},"2028-12",{"name":213,"class":41},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":53,"phases":224,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":42},"100640257","community-based-eye-screening-with-structured-referral-tracking-for-preventing-avoidable-blindness-in-adults-in-rawalpindi-pakistan-100640257","NCT07611682","Community-Based Eye Screening With Structured Referral Tracking for Preventing Avoidable Blindness in Adults in Rawalpindi, Pakistan","Community-Based Eye Screening With a Structured Referral Tracking Intervention for the Prevention of Avoidable Blindness Among Adults in Rawalpindi District, Pakistan","SIGHT","Inclusion Criteria:\n\n* Adults aged 18 years or above\n* Individuals diagnosed with visual impairment or eye conditions requiring referral to a tertiary eye care facility\n* Permanent residents of Rawalpindi District, Pakistan\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Individuals already undergoing treatment for the identified eye condition\n* Individuals requiring emergency ophthalmic care\n* Severe systemic or physical illness limiting follow-up\n* Individuals unable to provide informed consent",{"count":223,"type":21},500,[55],"This cluster randomized controlled trial aims to evaluate the effectiveness of a Structured Referral Tracking (SRT) intervention in improving referral completion among adults identified with avoidable blindness during community-based eye screening camps in Rawalpindi District, Pakistan. Ten community clusters will be randomized into intervention and control groups. Participants in the intervention group will receive structured referral counseling, weekly reminder calls or messages, and customized referral guidance for eight weeks, while the control group will receive standard referral procedures. The primary outcome is referral completion at a tertiary eye hospital within eight weeks after screening. Secondary outcomes include knowledge regarding avoidable blindness, treatment satisfaction, feasibility, acceptability, and barriers influencing referral completion.",[25,227,228],"Refractive Error","Diabetic Retinopathy",[230,231,25,227,228,232,233],"Community Eye Screening","Avoidable Blindness","Referral System","Structured Referral Tracking",{"date":235,"type":34},"2026-06-04",{"date":237,"type":21},"2026-06-01",{"date":239,"type":21},"2026-11-30",{"name":241,"class":41},"Health Services Academy, Islamabad, Pakistan",{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":262},"100591980","capella-scientia-development-study-100591980","NCT06987474","Capella Scientia Development Study","Capella Scientia (SCDX) Development Study","Inclusion Criteria:\n\n* Able to understand and sign an IRB\u002FIEC approved consent form;\n* Willing and able to attend study visit(s) as required by the protocol;\n* Consenting age at the jurisdiction of study site;\n* Other group-specific, protocol required inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Women of child-bearing potential;\n* Unable to fixate due to nystagmus or other eye movement abnormality (e.g., significant strabismus);\n* Unclear optical media preventing data capture from all devices in the study;\n* Contraindicated for pupil dilation (e.g., narrow angles, allergies) per investigator's clinical judgment;\n* Any ocular disease and\u002For condition that, in the investigator's clinical judgment, may put the subject at significant risk, may compromise study results, or may interfere significantly with the subject's participation in the study;\n* Other group-specific, protocol required exclusion criteria may apply.",{"count":100,"type":21},"This study involves collecting biometry and aberration data using the next generation biometer, Unity DX.",[25],"2026-05-21",{"date":254,"type":34},"2026-05-26",{"date":256,"type":34},"2025-07-30",{"date":258,"type":21},"2027-05",{"name":260,"class":261},"Alcon Research","INDUSTRY",4,{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":271,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":53,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":283},"100550418","multicentric-clinical-investigation-to-assess-safety-and-performance-of-lux-highadd-iol-100550418","NCT06446817","Multicentric Clinical Investigation to Assess Safety and Performance of Lux HighAdd IOL","Multicentric Clinical Investigation to Determine Safety and Efficacy of a Hydrophobic Acrylic Multifocal Intraocular Lens","HIGHADD","Inclusion Criteria:\n\n* Subject aged 50 or over on the day of inclusion, presenting a bilateral cataract, qualified for bilateral implantation\n* No ocular comorbidity possibly affecting the study results\n* Fit within the available IOL diopter range\n* Have had no previous refractive surgery\n* Regular corneal astigmatism ≤1.0 dioptres\n* Clear intraocular media other than cataract\n* Availability, willingness and sufficient cognitive awareness to comply with examination procedures\n* Ability to attend all study follow-ups\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Ocular surface disease potentially affecting study results\n* Pre-existing ocular pathology or history of pathology potentially affecting the study results\n* Acute or chronic disease or illness that would increase risk or confound study results\n* Subjects who may be reasonably expected to require a secondary surgical intervention at any time during the investigation (other than YAG capsulotomy)\n* Axial lengths and keratometry such as the IOL spherical power is not in the range of 16 to 26 D\n* Instability of keratometry or biometry measurements\n* Traumatic cataract\n* Amblyopia\n* History of ocular trauma or any prior ocular surgery including refractive procedures\n* Capsular or zonular abnormalities that may affect postoperative centration or tilt of the lens\n* Pupil abnormalities\n* Systemic or ocular medication that could modify pupil dynamics\n* Expected complicated surgery or complicated surgery\n* Concurrent participation in another drug or device investigation","50 Years",{"count":273,"type":21},57,[55],"The study purpose is to demonstrate safety and performance of bilateral implantation of LuxHighAdd intraocular lens compared with the LuxGood Monofocal lens.",[25],{"date":254,"type":34},{"date":279,"type":34},"2024-12-19",{"date":211,"type":21},{"name":282,"class":261},"Cutting Edge SAS",3,{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":17,"minAge":291,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":53,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":42},"100640397","binaural-sound-during-phacoemulsification-and-posterior-chamber-lens-implantation-in-geriatric-patients-100640397","NCT07609186","Binaural Sound During Phacoemulsification and Posterior Chamber Lens Implantation in Geriatric Patients","Effect of Binaural Sound During Phacoemulsification and Posterior Chamber Lens Implantation on Postoperative Patient Satisfaction in Geriatric Patients: a Single-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients scheduled to undergo their first phacoemulsification and posterior chamber intraocular lens implantation (PE \\& PCL) under monitored anesthesia care (MAC).\n* Patients aged 65 years or older.\n* Patients who fully understand the study and voluntarily provide written informed consent to participate.\n\nExclusion Criteria:\n\n* Patients undergoing their second consecutive PE \\& PCL surgery.\n* Patients with hearing loss, hearing impairment, or those who use hearing aids.\n* Patients unable to wear earphones due to diseases of the external auditory canal.\n* Patients who chronically use hypnotics or sedatives.\n* Patients with a history of obstructive sleep apnea or a Body Mass Index of 35 kg\u002Fm² or higher.\n* Patients with a history of alcohol or drug dependence.\n* Patients with a history of epilepsy or seizure disorders.\n* Patients who are unable to complete a written questionnaire.\n* Patients deemed unsuitable for participation in the clinical trial based on the investigator's clinical judgment.","65 Years",{"count":293,"type":21},60,[55],"The purpose of this study is to evaluate the effects of binaural beats on patient satisfaction and intraoperative comfort in patients aged 65 years or older undergoing cataract surgery (phacoemulsification and posterior chamber intraocular lens implantation) under monitored anesthesia care (MAC) with propofol.\n\nParticipants are randomly assigned to either a binaural beat group or a control group. The binaural beat group will wear earphones and listen to binaural beats from the time they arrive at the operating room until the surgery is completed. The control group will wear identical earphones but will not receive any auditory stimulus.\n\nDuring the procedure, standard vital signs and the bispectral index (BIS) will be continuously monitored in both groups. Following the surgery, the investigators will assess the patients' overall satisfaction using a 7-point Likert scale. Secondary assessments include patient preference for the anesthesia method, intraoperative pain intensity, sedation level, anxiety level, and quality of life (EQ-VAS) measured by a visual analogue scale. Any surgery-related discomfort or adverse events will also be recorded and compared between the two groups.",[25,297,298],"Binaural Beats","Geriatric Anesthesia","2026-05-19",{"date":301,"type":34},"2026-05-27",{"date":303,"type":34},"2025-08-07",{"date":305,"type":21},"2026-07-08",{"name":307,"class":41},"Seoul National University Hospital",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":314,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":53,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":262},"100638560","clinical-evaluation-of-a-novel-trifocal-iol-100638560","NCT07587138","Clinical Evaluation of a Novel Trifocal IOL","Key Inclusion Criteria:\n\n* The calculated power needed for the artificial lens (IOL) must be between +15.0 and +25.0 D in each eye, designed to bring subject vision as close to \"0.0\" (neutral) as possible, meaning they will not be strongly nearsighted or farsighted after surgery.\n* Subjects must have low levels of astigmatism (misshapen cornea) in the eyes (less than 1.00 D).\n* In the doctor's opinion, the subjects have the potential to achieve good vision (0.2 logMAR, which is roughly 20\u002F32 Snellen or better) in each eye after the surgery, when wearing the best possible spectacles or contact lenses.\n* Other protocol-specified inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Clinically significant corneal diseases which may, according to the investigator's medical opinion, adversely affect visual outcomes.\n* Any ocular or systemic health condition or medical issue that, in the investigator's medical opinion, could make the study results unreliable, prevent the person from finishing the study, or increase their safety risk.\n* People who want to have one eye set for distance vision and the other for near vision.\n* The doctor expects significant blurry vision (astigmatism) after the procedure.\n* Other protocol-specified exclusion criteria may apply.","22 Years",{"count":316,"type":21},66,[55],"The purpose of this study is to understand the visual outcomes of the investigational intraocular lens (IOL) Model LPYWT0 when compared to the commercially marketed Clareon PanOptix Pro IOL Model PXYWT0.",[320,25],"Aphakia","2026-05-14",{"date":323,"type":34},"2026-05-18",{"date":325,"type":21},"2026-10",{"date":327,"type":21},"2027-07",{"name":260,"class":261},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":53,"phases":338,"briefSummary":339,"conditions":340,"keywords":342,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":354,"leadSponsor":356,"locationsCount":42},"100618563","strengthening-community--to--hospital-eye-care-pathways-from-boko-eye-care-center-in-rural-assam-100618563","NCT07333248","Strengthening Community- to- Hospital Eye Care Pathways From Boko Eye Care Center in Rural Assam","Strengthening Community -to- Hospital Eye Care Pathways From Boko Eye Care Center in Rural Assam - From Referral to Treatment","Inclusion Criteria:\n\nAdults diagnosed with eye conditions requiring referral or surgical treatment.\n\nExclusion Criteria:\n\nPatients requiring emergency treatment, patients medically unfit for surgery, or patients unwilling to participate.\n\nEligibility: Enrolment criteria: Participants will be enrolled consecutively at the time of screening in community outreach camps and at the Boko Eye Care Center if they meet the following operational criteria:\n\ni. Adult (≥18 years) with a diagnosed eye condition requiring referral to Sri Sankaradeva Nethralaya for tertiary evaluation or surgical treatment, as determined by the examining optometrist\u002Fophthalmologist.\n\nii. Resident of the Boko Eye Care Center catchment area (villages linked to the Eye Care Center under Sri Sankaradeva Nethralaya outreach).\n\niii. Patients willing to provide informed consent to participate in the study and to allow follow-up for referral completion and surgical acceptance outcomes.",{"count":337,"type":21},2000,[55],"This operational research project aims to strengthen continuity of eye care delivery between community screening and hospital-based treatment in rural Assam by redesigning referral pathways from the Boko Eye Care Center (ECC) to Sri Sankaradeva Nethralaya (SSDN) base hospital. Despite active outreach in the Boko region from the Boko ECC through conducting regular outreach screenings, less than 30 percent of patients referred to the base hospital actually arrive for evaluation and less than 25 percent of those advised for surgery proceed to treatment. The proposed study addresses these gaps by examining behavioural, structural and logistical barriers to referral completion and surgical uptake, and by implementing a coordinated patient-centered referral and engagement strategy.\n\nThe proposed intervention comprises of five sequential components: (1) root cause analysis to identify bottlenecks and facilitators in the current referral pathway, (2) community engagement activities to improve awareness and proactive health-seeking behaviour, (3) implementation of an integrated referral and engagement model supported by trained community team and structured referral tracking, (4) strengthening referral completion through patient navigation, scheduled transport and follow-up reminders, and (5) enhancement of surgical acceptance through standardized counseling, affordability support and social reinforcement. The outcomes will be measured prospectively, focusing on increase in hospital footfall from the Boko catchment area, proportion of referred patients who complete hospital visits, and proportion of patients who were advised for surgery and had undergone the procedure. The proposed project aims to achieve a minimum of 70 percent referral completion and 45 percent surgical conversion by the end of the 36-month study period.",[25,341],"Refractive Errors",[343,344,345,346,347,348,349,350],"Referral completion","Cataract surgery uptake","Patient navigation","Community engagement","Rural eye care","Surgical acceptance","Assam","LMIC","2026-05-11",{"date":321,"type":34},{"date":110,"type":21},{"date":355,"type":21},"2028-01-31",{"name":357,"class":41},"Seva Canada Society",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":17,"minAge":366,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":383,"locationsCount":42},"100639027","evaluation-of-the-effectiveness-of-three-tear-substitute-formulations-in-postoperative-discomfort-after-cataract-surgery-100639027","NCT07581548","Evaluation of the Effectiveness of Three Tear Substitute Formulations in Postoperative Discomfort After Cataract Surgery","Evaluation of the Effectiveness of Three Tear Substitute Formulations in Postoperative Discomfort After Cataract Surgery: A Non- Interventional, Observational Study","DRY-CAT","Inclusion Criteria:\n\nDiagnosis of senile cataract with stage 2 or 3 nuclear opalescence according to the - Lens Opacities Classification System III (LOCS-3) grading scale\n\nExclusion Criteria:\n\n1. Former incisional surgery\n2. Former diagnosis of corneal disease\n3. Autoimmune diseases\n4. Mental diseases","45 Years","85 Years",{"count":369,"type":21},300,"The primary objective of this study is the assessment of three tear substitute formulations in terms of postoperative discomfort following cataract extraction surgery by means of phacoemulsification and intraocular lens implantation.",[25,104],[373,374,375,376],"dry eye","cataract surgery","sodium hyaluronate","artificial tears","2026-05-06",{"date":379,"type":34},"2026-05-12",{"date":381,"type":21},"2026-05-01",{"date":70,"type":21},{"name":384,"class":41},"Democritus University of Thrace",{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":394,"conditions":395,"keywords":401,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":42},"100563464","artificial-intelligence-for-highly-myopic-cataract-100563464","NCT06616506","Artificial Intelligence for Highly Myopic Cataract","AI-HMC","Inclusion Criteria:\n\nAxial length ≥ 26 mm and patients with high myopia complicated by cataracts who visit our hospital.\n\nPreoperative anterior segment photography and cataract severity assessment, along with fundus OCT examination, have been performed.\n\nIf surgical treatment is conducted, the postoperative follow-up period should be no less than 1 month.\n\nThere are no missing clinical data before and after the surgery.\n\nExclusion Criteria:\n\nPatients who are unable to cooperate with the required examinations for this study.",{"count":393,"type":21},500000,"This study aims to establish a multi-center artificial intelligence model for the accurate calculation of intraocular lens and its clinical application in highly myopic cataract, so as to improve the accuracy of the prediction of postoperative diopter in highly myopic cataract patients.",[25,396,397,398,399,400],"High Myopia","Myopia","Automatic Judgement","Risk Reduction","Diagnoses Disease",[402,403,404,405],"highly myopic cataract","artificial intelligence","cataract","big data",{"date":351,"type":34},{"date":408,"type":34},"2016-01-01",{"date":410,"type":21},"2035-12-31",{"name":412,"class":41},"Shanghai High Myopia Study Group",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":420,"maxAge":421,"enrollmentInfo":422,"targetDuration":424,"studyType":22,"phases":4,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":42},"100290540","shanghai-high-myopia-study-100290540","NCT03062085","Shanghai High Myopia Study","Visual Outcome Evaluation and Genetic Analysis: Shanghai High Myopia Study","Inclusion Criteria:\n\n* Clinical diagnosis of cataract\n* Must be able to cooperate with the ophthalmic examination\n\nExclusion Criteria:\n\n* Clinical diagnosis of mental illness\n* Mentally disabled","20 Years","100 Years",{"count":423,"type":21},60000,"5 Years","The purpose of this study is to evaluate the long-term visual outcome of the cataract surgery using a large-scale and comprehensive database of high myopic cataract and age-related cataract patients. The investigators will further investigate into the various genetic and environmental factors that may contribute to the pathogenesis of high myopic cataract.",[396,25,427,428],"Visual Outcome","Genetic Anticipation",{"date":351,"type":34},{"date":431,"type":34},"2015-01-01",{"date":433,"type":21},"2045-12-31",{"name":412,"class":41},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":181,"sex":17,"minAge":443,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":53,"phases":446,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":458,"locationsCount":460},"100594099","developing-and-testing-a-model-to-identify-preventive-vision-loss-among-older-patients-in-general-practice-100594099","NCT07015034","Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice","Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice (DETECT)","DETECT","Inclusion Criteria:\n\n* +70 years\n* One or more chronic diseases\n* Are followed by GP du to chronic disease\n\nExclusion Criteria:\n\n* Dementia diagnosis\n* Known eye-diseases or are currently followed by private ophtalmologist\n* Not able to understand Danish","70 Years",{"count":445,"type":21},460,[55],"In this cohort study, the investigators will test vision screenings in Danish general practice for patients over 70 years of age with minimum one chronic condition. The main outcome is detection of vision impairment and secondary outcome is detection of conditions needing ophthalmologic follow-up but not presenting vision impairment at present time.",[449,450,451,25,228],"Vision Impairment and Blindness","Glaucoma","Age-Related Macular Degeneration","2026-04-23",{"date":454,"type":34},"2026-04-29",{"date":456,"type":34},"2024-05-15",{"date":135,"type":21},{"name":459,"class":41},"University of Copenhagen",2,{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":53,"phases":470,"briefSummary":471,"conditions":472,"keywords":482,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":42},"100635703","dexmedetomidine-and-propofol-for-sedation-in-cataract-surgery-100635703","NCT07556133","Dexmedetomidine and Propofol for Sedation in Cataract Surgery.","Dexmedetomidine vs Propofol for Sedation in Cataract Surgery : a Prospective Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adults undergoing cataract surgery\n\nExclusion Criteria:\n\n* Severe hepatic insufficiency\n* Third degree AV block\n* Patient refusal",{"count":469,"type":21},1000,[55],"The goal of this prospective, randomized, single-blinded is to learn if there is an ideal sedation protocol in cataract surgery in adults.\n\nThe main questions it aims to answer are:\n\n* Does the combination of Dexmedetomidine and Propofol affect significantly Ramsay sedation scale, compared to Dexmedetomidine and compared to Propofol?\n* How does each sedation protocol affect hemodynamics? (Heart rate and blood pressure)\n* Are respiratory events more common in a certain group?\n* Is the surgeon's satisfaction similar among groups?\n* Are adverse effects (bradycardia, hypotension, nausea) more common in a certain group?\n\nResearchers will compare 3 sedation protocols : Dexmedetomidine versus Propofol versus the combination of these 2 drugs and to see if one protocol is overall superior to the others. Fentanyl will also be used in all 3 sedation protocols.\n\nParticipants will :\n\n* Receive one of these three protocols\n* Be operated for one or both eyes\n* Monitored during the whole surgery and in the recovery room\n* Be evaluated by the Ramsay sedation scale by a trained Anesthesiologist or CRNA during surgery and in the recovery room Surgeons will be asked about how much they were satisfied.",[473,25,474,475,476,477,478,479,480,481],"Sedation","Hemodynamic","Hemodynamic Changes","Dexmedetomidine","Propofol Dosage","Fentanyl","Bradycardia","Tachycardia","Nausea and Vomiting",[483,25,484,485,486],"Dexmedetomidine and propofol in cataract surgery","sedation","Dexmedetomidine in cataract surgery","Sedation for cataract surgery","2026-04-21",{"date":454,"type":34},{"date":490,"type":34},"2025-11-09",{"date":492,"type":21},"2026-12-09",{"name":494,"class":41},"Saint-Joseph University",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":53,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":283},"100602665","impact-of-capsular-tension-ring-on-intraocular-lens-position-in-retinitis-pigmentosa-cataract-patients-100602665","NCT07126470","Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients","Effect of Capsular Tension Ring Implantation on Postoperative IOL Position in Retinitis Pigmentosa Patients With Cataract: a Multi-center, Randomized, Self-controlled Study","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of retinitis pigmentosa (RP).\n* Bilateral cataract meeting the indications for IOL implantation.\n* Willingness to participate in the study and provision of signed informed consent.\n\nExclusion Criteria:\n\n* History of intraocular surgery.\n* Severe zonular weakness (e.g., zonular dialysis \\>90°, lens subluxation\u002Fdislocation)\n* Other ocular comorbidity: such as pseudoexfoliation syndrome, ocular trauma, corneal dystrophies, uveitis, etc.\n* Severe systemic diseases: such as severe hypertension, diabetes, heart disease, Alzheimer's, Parkinson, etc.",{"count":503,"type":21},88,[55],"This is a self-controlled randomized clinical trial to investigate the effect of capsular tension ring (CTR) implantation on intraocular lens (IOL) position in cataract patients with retinitis pigmentosa(RP). Each patient will receive CTR implantation in one eye, with the fellow eye serving as control. Postoperative outcomes, including visual acuity, IOL position, and postoperative complications will be compared between eyes.",[25,507],"Retinitis Pigmentosa (RP)","2026-04-20",{"date":452,"type":34},{"date":511,"type":34},"2025-08-25",{"date":513,"type":21},"2027-08",{"name":213,"class":41},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":53,"phases":524,"briefSummary":525,"conditions":526,"keywords":527,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":4},"100634819","effect-of-surgical-planning-prompts-on-elective-surgery-acceptance-rate-100634819","NCT07544641","Effect of Surgical Planning Prompts on Elective Surgery Acceptance Rate","Impact of Patient Surgical Planning on Elective Surgery Acceptance Rate: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 1\\. Diagnosed with one of the following: age-related cataract, complicated cataract, traumatic cataract, metabolic cataract, or congenital cataract 2. Age 18+ years 3. Baseline intraocular pressure (IOP) ≤ 21 mmHg 4. Axial length 20-30 mm 5. No intraocular surgery within the past 3 months 6. Meets at least ONE of the following functional criteria:\n\n  1. Best Corrected Visual Acuity (BCVA) ≤ 0.5 and vision loss primarily attributable to cataract\n  2. Posterior subcapsular cataract with patient-reported significant impact from glare, halos, or impaired night driving\n  3. Patient-reported significant decrease in contrast sensitivity\n  4. Anisometropia or refractive error, and patient reports inability to accept spectacle correction impacting reading, daily chores, TV viewing, driving, or outdoor activities\n  5. Cataract interfering with fundus examination\u002Ftreatment (e.g., diabetic retinopathy, macular disease, uveitis)\n  6. Lens with risk of inducing glaucoma (shallow anterior chamber with family history or fellow-eye history of angle-closure, lens dislocation\u002Fsubluxation, hypermature cataract)\n\nExclusion Criteria:\n\n* Already decided to undergo or decline surgery at time of initial consultation",{"count":523,"type":21},268,[55],"This randomized, double-blind, controlled trial investigates whether prompting patients facing elective cataract surgery to articulate their specific conditions for choosing surgery (a structured self-reflection intervention commonly used in Shared Decision-Making) affects their subsequent decision to undergo the procedure. Eligible cataract patients who have been informed of surgical indications at an outpatient visit will be randomly assigned 1:1 to an intervention group (structured writing about personal conditions for accepting surgery) or a control group (no writing task). Both groups read the same standardized information about cataract diagnosis and treatment, and both complete the same set of follow-up questionnaire items. Three treating physicians independently rate their degree of surgical recommendation for each patient; these ratings along with baseline clinical measures are included as covariates in the analysis. The primary outcome is whether participants register for cataract surgery within 6 months of their initial outpatient consultation. Secondary outcomes include self-reported understanding of the condition, clarity of treatment plan, condition-related anxiety, perceived urgency, perceived helpfulness of the consultation, semantic analysis of written responses, and patient experience measures.",[25],[25,528,529,530,531,532,533],"Shared Decision-Making","Elective Surgery","Surgical Planning","Decision Aid","Patient Autonomy","Behavioral Intervention","2026-04-15",{"date":536,"type":34},"2026-04-22",{"date":538,"type":21},"2026-04-13",{"date":540,"type":21},"2027-04",{"name":542,"class":41},"Tongji University",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":181,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":4},"100634589","study-on-eye-brain-cross-organ-mapping-and-systemic-disease-association-based-on-multimodal-big-data-100634589","NCT07541651","Study on Eye-Brain Cross-Organ Mapping and Systemic Disease Association Based on Multimodal Big Data","Inclusion Criteria:\n\n* Eye data: Images must meet quality standards (no significant artifacts, key structures clearly visible), with complete examination records (including examination date and device model).\n* Brain data: MR images must be free of motion artifacts, with complete sequences (at least including T1-weighted imaging and MRA), and reports must confirm no technical issues.\n* Eye-brain paired cohort: Must contain at least one type of eye image (including CFP, OCT, or OCTA) along with brain MR data, and be linkable to a unique identifier and clinical information in the database\n* Clinical data: Clinical information (such as core biochemical indicators, demographic information, and necessary questionnaire items) must have a missing rate ≤30%, with standardized and clear ICD diagnostic codes, complete laboratory test data, and medical order information (including medication or follow-up recommendations)\n* Prior to initial inclusion in the study, participants must have no history of severe organic diseases (including non-curable or end-stage malignancies, severe heart failure (NYHA Class III-IV), end-stage renal disease (CKD Stage 5), decompensated cirrhosis, or significant functional impairment due to severe cerebrovascular disease sequelae, etc.).\n\nExclusion Criteria:\n\n* Ocular examinations in which key features cannot be identified due to conditions such as cataracts or vitreous hemorrhage brain MR images deemed unacceptable in quality due to factors such as metal implants\n* Clinical information (including core biochemical indicators, demographic details, essential questionnaire items, etc.) with a missing rate exceeding 30%\n* Individuals who are pregnant or lactating, those with ocular trauma, congenital ocular malformations, or severe organic diseases.",{"count":550,"type":21},208000,"This project integrates multimodal eye data (CFP, OCT, OCTA) from 50,000 cases, brain MR data from 150,000 cases, and ICD diagnoses, medical orders, and test results from an eye-brain paired cohort of 8,000 cases to construct an eye-brain cross-modal mapping model and an eye-brain-systemic disease association model. It aims to clarify the quantitative associations between multimodal ocular features and brain structural and vascular characteristics as well as systemic disease ICD diagnoses, thereby uncovering the cross-organ and cross-modal linkage mechanisms between the eye and brain. Ultimately, it seeks to achieve mapping and prediction of brain imaging features based on ocular data, enable ocular-based diagnosis and prediction of various diseases, and contribute significantly to early disease screening, risk stratification, and optimization of clinical diagnosis and treatment.",[25,553,554,555,556],"Vitreous Hemorrhage","Diabetic Eye Diseases","Cerebral Small Vessel Disease","Cerebrovascular Stenosis","2026-04-14",{"date":487,"type":34},{"date":560,"type":21},"2026-04-25",{"date":562,"type":21},"2029-12-31",{"name":564,"class":41},"Beijing Friendship Hospital",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":17,"minAge":420,"maxAge":50,"enrollmentInfo":572,"targetDuration":4,"studyType":53,"phases":574,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":460},"100571398","functional-iol-implantation-in-patients-with-epiretinal-membrane-100571398","NCT06719739","Functional IOL Implantation in Patients With Epiretinal Membrane","Clinical Outcomes in Cataract Patients With Macular Epiretinal Membrane After Implantation of Functional Intraocular Lenses","Inclusion Criteria:\n\n* Requirement for cataract extraction\n* Age \\> 40 years\n* Axial length in 21mm to 25mm\n* ERM\n\nExclusion Criteria:\n\n* Residual corneal astigmatism \\> 1.0 D\n* Amblyopia\n* Previous ocular surgery\n* Other ocular pathologies apart from mERM, such as diabetic retinopathy, macular degeneration, glaucoma with field defects\n* Requirements for further ocular surgery (other than Nd:YAG capsulotomy) or retinal laser treatments during the study",{"count":573,"type":21},90,[55],"We have designed this prospective study to evaluate macular involvement and epiretinal membrane (ERM) grading by OCT in eyes with ERM and to compare clinical outcomes after implantation of Enhance IOL with standard monofocal IOL in eyes with ERM grading preoperatively, aiming to find out whether functional IOL is benefit for patients with ERM.",[25,577,578],"Intraocular Lens Complication","Epiretinal Membrane","2026-04-02",{"date":581,"type":34},"2026-04-08",{"date":583,"type":34},"2024-09-21",{"date":585,"type":21},"2026-09-21",{"name":587,"class":41},"Eye & ENT Hospital of Fudan University",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":17,"minAge":291,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":53,"phases":597,"briefSummary":599,"conditions":600,"keywords":602,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":42},"100599110","phase-3-intranasal-dexmedetomidine-on-blood-pressure-in-elderly-hypertensive-patients-undergoing-cataract-surgery-100599110","NCT07080229","Intranasal Dexmedetomidine on Blood Pressure in Elderly Hypertensive Patients Undergoing Cataract Surgery","The Effect of Intranasal Dexmedetomidine Compared to Placebo on Blood Pressure in Elderly Hypertensive Patients Undergoing Cataract Surgery: A Double-Blind Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients aged ≥65 years.\n2. Patients who will have stage 2 hypertension as per ACC\u002FAHA guidelines (Systolic BP \\> 140 and Diastolic BP\\> 90 mmHg)\n3. Elective cataract surgery under local anesthesia.\n4. American Society of Anesthesiologists (ASA) physical status II or III.\n\nExclusion Criteria:\n\n1. Allergy or contraindication to dexmedetomidine.\n2. Significant baseline bradycardia (\\\u003C50 bpm) or arrhythmias.\n3. Use of sedative or anxiolytic medications.\n4. History of severe hepatic, renal, or cerebrovascular diseases.",{"count":596,"type":21},126,[598],"PHASE3","Cataract surgery in elderly patients with controlled hypertension carries a risk of hemodynamic instability, particularly fluctuations in mean arterial blood pressure (MAP). Dexmedetomidine, a selective α2-adrenergic agonist, offers hemodynamic stabilization and sedation when administered intranasally and provides a simple and non-invasive premedication option.\n\nThis study evaluates the effects of intranasal dexmedetomidine on perioperative mean arterial blood pressure in patients undergoing cataract surgeries.\n\nResearch Question:\n\nDoes intranasal dexmedetomidine premedication control blood pressure in elderly hypertensive patients undergoing cataract surgery?\n\nResearch Hypothesis:\n\nIntranasal dexmedetomidine significantly reduces MAP and improves secondary outcomes compared to placebo.\n\nPrimary Objective: To evaluate the efficacy of intranasal Dexmedetomidine as a premedication to control hypertension in elderly patients scheduled for cataract surgery.\n\nSecondary Objectives: 1. To assess surgery cancellation rates. 2. To evaluate satisfaction levels among patients, anesthesiologists, and surgeons using the Modified Observer's assessment of alertness\u002Fsedation scale (MOAA\u002FS). 3- To evaluate the effect of intranasal dexmedetomidine on HR multiple readings starting from preoperative hold area till 2 hours postoperatively.\n\nThis randomized, double-blinded clinical trial will include 126 elderly hypertensive patients (≥65 years) undergoing cataract surgery under local anesthesia. Inclusion Criteria will consist of patients aged ≥65 years, ASA II or III, stage 2 hypertension as per ACC \u002F AHA guidelines (SBP\\>140 and DBP\\> 90 mmHg), undergoing elective cataract surgery under local anesthesia. Exclusion Criteria will include allergy or contraindication to dexmedetomidine, significant baseline bradycardia (\\\u003C50 bpm) or arrhythmia, use of sedative or anxiolytic medications, history of severe hepatic, renal, or cerebrovascular disease. Participants will be randomly assigned to receive either intranasal dexmedetomidine (1 mcg\u002Fkg ideal body weight) or a placebo (normal saline) 30 minutes before surgery. MAP, HR, and SpO₂ will be recorded at multiple perioperative intervals, and surgical cancellation rates, satisfaction levels will be noted, surgical duration, and hospital stay will be documented.",[25,601],"Hypertension",[25,601,603,604],"Intranasal Dexmedetomidine","Elderly","2026-04-01",{"date":607,"type":34},"2026-04-07",{"date":609,"type":34},"2025-07-16",{"date":611,"type":21},"2026-05",{"name":613,"class":41},"Suez Canal University",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":181,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":624,"conditions":625,"keywords":629,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":636,"completionDateStruct":637,"leadSponsor":639,"locationsCount":460},"100631218","artificial-intelligence-assisted-diagnosis-in-ophthalmology-100631218","NCT07497815","Artificial Intelligence-assisted Diagnosis in Ophthalmology","Development and Validation of an Artificial Intelligence-assisted Diagnostic System for Ophthalmic Pathologies","AI-OPHTH-CR","Inclusion Criteria:\n\n* Image corresponds to patient ≥18 years of age at time of capture\n* Image modality is one of: fundus photography, posterior segment OCT, anterior segment photography, automated perimetry, or video-OCT\n* Image quality sufficient for diagnostic interpretation (adequate resolution, focus, illumination, complete visualization of anatomical area of interest, no major artifacts)\n* Minimum clinical data available (age or age group, sex, and diagnosis or clinical indication)\n* Image captured during routine clinical care (not specifically for research)\n* No patient objection to use of medical data for research (when applicable per center policy)\n\nExclusion Criteria:\n\nCLINICAL:\n\n* Images from eyes with recent intraocular surgery (\\\u003C3 months)\n* Images from eyes with severe ocular trauma distorting anatomy\n* Images from patients with rare or unique ocular pathologies not allowing generalization\n* Images post-recent laser treatment where acute changes may confuse analysis\n\nTECHNICAL:\n\n* Severely degraded image quality (extreme blur, severe under\u002Foverexposure, major artifacts preventing interpretation)\n* Duplicate images of same eye on same date\n* Images with missing or clearly erroneous metadata\n* Images in non-standard or corrupted formats that cannot be processed\n\nSex\u002FGender: All Minimum Age: 18 Years Maximum Age: No limit Accepts Healthy Volunteers: Yes (images of healthy eyes without pathology are included as controls)",{"count":623,"type":21},15000,"This is a retrospective, multicenter, observational study designed to develop and validate an artificial intelligence (AI) system capable of detecting and classifying major ophthalmic diseases (glaucoma, cataract, diabetic retinopathy, and other retinal pathologies) in the Costa Rican population. The study will use approximately 15,000 existing medical images from digital archives of two ophthalmic centers in Costa Rica, without active participant recruitment or capture of new images.\n\nThe primary motivation is that AI systems developed in other countries (primarily Asian, European, or North American populations) do not necessarily perform with the same accuracy when applied to Latin American populations. This study seeks to establish a precedent for the importance of locally validating any medical AI technology before clinical implementation.",[626,627,450,628,25],"Macular Degeneration","Diabetic Retinopathy (DR)","Keratoconus",[630,631,632,633],"artificial inteligence","ophthalmology","imaging","bias","2026-03-26",{"date":605,"type":34},{"date":381,"type":21},{"date":638,"type":21},"2029-05-01",{"name":640,"class":261},"Marisse Masis-Solano"]